Key takeaways
- ~5–10K Estimated diagnosed US classic Fabry patients (~1:40,000 males) — later-onset largely undiagnosed · NORD / registry
- ~35–50% Fabry patients with a migalastat-amenable GLA mutation — the oral-eligibility gate · FACETS / ATTRACT
- X-linked GLA inheritance — female heterozygotes develop multi-organ disease, ~decade later than males · FOS
Fabry is one disease with two faces: a classic multi-organ form presenting in childhood, and a later-onset, cardiac-predominant form that is largely undiagnosed — with treatment eligibility split further by whether the GLA mutation is amenable to an oral chaperone.
Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations that reduce or abolish alpha-galactosidase A activity, allowing globotriaosylceramide (GL-3) to accumulate in the vascular endothelium, kidney, heart, and nervous system. Classic Fabry (near-absent enzyme activity) presents in childhood with neuropathic pain, angiokeratoma, and hypohidrosis, progressing over decades to renal failure, hypertrophic cardiomyopathy, and stroke. US prevalence of diagnosed classic Fabry is estimated at ~5,000–10,000 patients (about 1:40,000 males), but this counts only the recognised population.
The larger, quieter story is the later-onset phenotype. Patients with residual enzyme activity often present in the fifth or sixth decade with isolated cardiac disease (a hypertrophic-cardiomyopathy picture) or chronic kidney disease, and are frequently missed. Long-term registry data (the Fabry Outcome Survey) show the burden shifting from renal failure, historically the principal cause of death in affected men, toward cardiac disease as the leading cause in both sexes as renal management has improved. Because Fabry is X-linked, female heterozygotes are not merely carriers: many develop clinically significant multi-organ disease, typically about a decade later than males. Layered on top of phenotype is the treatment-eligibility split — roughly 35–50% of patients carry a GLA mutation amenable to the oral chaperone migalastat, the rest require intravenous enzyme replacement.
Fabry phenotype spectrum — presentation, organ burden, and treatment implication
| Phenotype | Prevalence (US est.) | Genetics & Onset | Organ Involvement | Diagnostic / Treatment Implication |
|---|---|---|---|---|
| Classic Fabry (males) | ~5,000–10,000 US (all forms); ~1:40,000 males | GLA mutation, near-absent alpha-Gal A; onset in childhood | Neuropathic pain and angiokeratoma first; then progressive renal, cardiac (LVH) and cerebrovascular (stroke) disease | Earliest treatment window; ERT or, if amenable, oral chaperone |
| Later-onset / cardiac variant | Far more common than classic; largely undiagnosed | Residual alpha-Gal A activity; presents 5th–6th decade | Predominantly cardiac (hypertrophic-cardiomyopathy phenotype); sometimes isolated renal disease | High-yield screening in unexplained LVH / HFpEF and CKD; frequently missed |
| Female heterozygotes | ~1:40,000; wide severity range | X-linked; random X-inactivation drives variability | Can develop full multi-organ disease, typically ~a decade later than males | Not carriers-only — require monitoring and treatment |
| Amenable-mutation subset | ~35–50% of Fabry patients | GLA mutation amenable to chaperoning (cell-based assay) | Same organ-risk profile as non-amenable patients | Oral migalastat-eligible vs ERT-only stratification |
Sources: Mehta A et al. FOS — Fabry Outcome Survey, J Med Genet 2009 (PMID 19473999); Germain DP et al. FACETS, NEJM 2016 (PMID 27509102); Hughes DA et al. ATTRACT, J Med Genet 2017 (PMID 27834756); NORD / Fabry registry epidemiology.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What is the size and phenotype split of the US Fabry population, and how large is the undiagnosed later-onset pool? • Classic vs later-onset prevalence estimates • the cardiac-predominant undiagnosed pool • registry and newborn-screening framing • recognised vs true prevalence gap
- How does the Fabry organ timeline (renal, cardiac, cerebrovascular) unfold, and where does it drive diagnosis and treatment initiation? • Organ-event sequence from childhood pain to renal and cardiac failure • the FOS-documented shift in cause of death • screening entry points in nephrology and cardiology
- How does GLA-mutation amenability stratify the population into oral-chaperone-eligible vs ERT-only? • Amenable-mutation fraction (~35–50%) • the cell-based assay gate • oral-eligible vs ERT-only segmentation and its commercial implications
What's inside
-
1 · Disease Biology & GLA / Alpha-Gal A Deficiency 4 pp
- Why GLA mutations that abolish alpha-galactosidase A activity let GL-3 accumulate in the endothelium, kidney, heart, and nerves.
- How classic Fabry's near-absent enzyme activity produces childhood-onset neuropathic pain, angiokeratoma, and hypohidrosis.
-
2 · US Epidemiology — Classic vs Later-Onset Phenotype 5 pp
- Why the ~5,000-10,000 diagnosed US classic Fabry estimate (about 1:40,000 males) counts only the recognised population.
- How the later-onset phenotype, presenting in the fifth or sixth decade, forms a larger but frequently undiagnosed pool.
-
3 · The Organ Timeline: Renal, Cardiac, Cerebrovascular 5 pp
- How classic Fabry progresses over decades from childhood pain to renal failure, hypertrophic cardiomyopathy, and stroke.
- Why Fabry Outcome Survey registry data show cardiac disease overtaking renal failure as the leading cause of death.
-
4 · Diagnostic Pathway & the Undiagnosed Cardiac Pool 4 pp
- Why later-onset patients presenting with isolated hypertrophic cardiomyopathy or chronic kidney disease are frequently missed.
- How high-yield screening in unexplained LVH, HFpEF, and CKD populations surfaces the undiagnosed cardiac-variant pool.
-
5 · GLA Amenability & Treatment-Eligibility Stratification 4 pp
- Why roughly 35-50% of Fabry patients carry a GLA mutation amenable to the oral chaperone migalastat.
- How the cell-based amenability assay splits patients into oral-migalastat-eligible versus enzyme-replacement-only groups.
-
6 · Female Heterozygotes & Family Screening 4 pp
- Why female GLA heterozygotes are not mere carriers, with many developing multi-organ disease about a decade later than males.
- How random X-inactivation drives the wide severity range seen among female Fabry heterozygotes.
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Fabry Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US Fabry patient population. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Fabry disease landscape is built from primary epidemiological sources, peer-reviewed clinical literature, and disease-registry data. Epidemiological estimates are triangulated across multiple sources; all figures carry source citations.
Key sources: Mehta A et al. Fabry Outcome Survey, J Med Genet 2009 (PMID 19473999); Germain DP et al. FACETS, NEJM 2016 (PMID 27509102); Hughes DA et al. ATTRACT, J Med Genet 2017 (PMID 27834756); the Fabry Outcome Survey and NORD Fabry disease entry.
- Fabry causes-of-death and natural-course data verified against FOS, J Med Genet 2009 (PMID 19473999)
- Migalastat amenable-mutation eligibility verified against FACETS, NEJM 2016 (PMID 27509102) and ATTRACT, J Med Genet 2017 (PMID 27834756)
- Classic prevalence (~1:40,000 males) triangulated against NORD and Fabry registry sources
- X-linked inheritance and female heterozygote involvement verified against peer-reviewed Fabry literature
Frequently asked questions
Epidemiology How common is Fabry disease in the US?
Diagnosed classic Fabry is estimated at about 5,000–10,000 US patients (roughly 1:40,000 males). Later-onset forms (which often present as isolated cardiac or kidney disease in the fifth or sixth decade) are more common but frequently undiagnosed, so the true prevalence is higher than the recognised population. Because Fabry is X-linked, female heterozygotes can also develop significant disease.
Disease What organs does Fabry disease affect, and in what order?
In classic Fabry, neuropathic pain and angiokeratoma appear in childhood, followed over decades by progressive kidney disease, hypertrophic cardiomyopathy, and stroke. Long-term registry data show the leading cause of death has shifted from renal failure toward cardiac disease as kidney management has improved. Later-onset patients may present with cardiac or renal disease alone.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.